IMMUNOMEDICS
Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.
IMMUNOMEDICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
1982-07-01
Address:
Morris Plains, New Jersey, United States
Country:
United States
Website Url:
http://www.immunomedics.com
Total Employee:
251+
Status:
Active
Contact:
973-605-8200
Total Funding:
30 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS COVID-19 Amazon Virginia Region Amazon S3 CDN Microsoft
Similar Organizations
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
CTI BioPharma
CTI BioPharma is a biopharmaceutical company developing oncology products for the treatment of cancer.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Stock Details
Investors List
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Immunomedics
Key Employee Changes
Official Site Inspections
http://www.immunomedics.com
- Host name: ec2-52-3-157-144.compute-1.amazonaws.com
- IP address: 52.3.157.144
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Immunomedics"
Immunomedics - Crunchbase Company Profile & Funding
Organization. Immunomedics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Immunomedics is a …See details»
Immunomedics, Inc. Company Profile - Dun & Bradstreet
Company Description: Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers. …See details»
Immunomedics, Inc. - AnnualReports.com
Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based …See details»
Gilead Sciences Completes Acquisition of Immunomedics Inc
Oct 23, 2020 Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers. The …See details»
Immunomedics Company Profile 2024: Valuation, …
Immunomedics General Information Description. Immunomedics was an operator of a fully integrated global commercial biopharmaceutical company intended to deliver new, life-changing treatments to people living with cancer around the …See details»
Governance Immunomedics, Inc. - MarketScreener.com
Nov 8, 2017 Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of …See details»
Company Immunomedics, Inc. - MarketScreener.com
Oct 22, 2020 Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of …See details»
Organization | Immunomedics - Purdue University
Organization Overview. First Clinical Trial. 1997 NCT00003337. First Marketed Drug. 2020 sacituzumab govitecan . First NDA Approval ... Immunomedics, Inc. | IMMUNOMEDICS INC …See details»
Gilead Sciences acquires Immunomedics - 2020-09-13 - Crunchbase
Oct 23, 2020 Immunomedics Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer. Acquiring …See details»
Immunomedics - Company Profile - Tracxn
Nov 27, 2024 Immunomedics - Developer of antibodies and antibody-drug conjugates for the treatment of cancer and autoimmune diseases. Raised funding over 2 rounds from 7 investors. …See details»
Immunomedics - Contacts, Employees, Board Members, Advisors …
Organization. Immunomedics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. …See details»
Immunomedics Company Profile - Office Locations, Competitors
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow creating humanized antibodies that can be used either alone …See details»
Gilead Sciences to Acquire Immunomedics
Sep 13, 2020 Immunomedics Contacts: Dr. Chau Cheng (862) 260-3727 [email protected] Darren Opland, PhD, Media (646) 627-8387 …See details»
Working for Immunomedics - Immunomedics
At Immunomedics, we continually seek excellence and process improvement within all departments across our organization. We offer challenging positions that range from …See details»
Immunomedics - Funding, Financials, Valuation & Investors
Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer. Search Crunchbase. ... How much …See details»
Immunomedics Inc Company Profile - GlobalData
Immunomedics is advancing IMMU-130 (labetuzumab govitecan) for colorectal cancer and IMMU-114 for hematologic cancers. It develops candidates based on its proprietary technologies …See details»
Immunomedics Company Overview, Contact Details
Dec 4, 2019 Immunomedics. Biotechnology Research New Jersey, United States 201-500 Employees. Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) …See details»
Immunomedics, Inc. - Drug pipelines, Patents, Clinical trials
Nov 1, 2024 Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the 68 Ga-labeled IMP288 peptide for immuno-PET …See details»
Linking Novel Medicines to Patients with Hard-to-Treat Cancers …
Immunomedics is a nearly 40-year-old company initially founded to focus on discovery and early research. In early 2017, a new board and management team began transforming the company …See details»